DNDN: apparently the PI was not enamored with provenge and that’s putting it mildly.
Is it clear that the clinician in question was/is a PI in the IMPACT study? I’m skeptical because it doesn’t make much sense for the PI of a trial that’s officially still in-progress to disparage the drug tested in the trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.